Bone mineral density in subjects using central nervous system-active medications

Area of Science:

• Bone health research
• Pharmacology
• Epidemiology

Background:

• Osteoporosis, defined by decreased bone mineral density (BMD), predicts fractures.
• Central nervous system (CNS) drugs like benzodiazepines, anticonvulsants, antidepressants, and opioids are linked to increased fracture risk.
• The direct impact of these CNS drugs on BMD versus other factors like falls remains unclear.

Purpose of the Study:

• To investigate the association between CNS medication use and BMD in a US population.
• To differentiate the effects of specific CNS drug classes on bone health.

Main Methods:

• Analysis of data from 7114 males and 7532 females aged 17+ from NHANES III (1988-1994).
• Measurement of total femoral BMD using dual-energy x-ray absorptiometry.
• Multivariable linear regression models adjusted for age, sex, and BMI to assess CNS medication effects on BMD.

Main Results:

• Anticonvulsant and opioid users showed significantly reduced BMD (0.92 g/cm2) compared to nonusers (0.95 g/cm2).
• No significant association was found between benzodiazepine or antidepressant use and reduced BMD.
• Adjustments for confounders confirmed these associations.

Conclusions:

• Anticonvulsants and opioids, but not benzodiazepines or antidepressants, are associated with significantly reduced BMD in a cross-sectional analysis.
• These findings highlight potential targets for fracture prevention strategies.
• Further research may explore mechanisms linking these specific CNS drugs to bone loss.